Table 2. The parameters of glucose metabolism after acarbose or metformin treatment in normal weight, overweight and obese patients with newly diagnosed type 2 diabetes.
| Parameters | BMI<24 | BMI 24–28 | BMI>28 | |||
| Acabose | Metfomin | Acabose | Metfomin | Acabose | Metfomin | |
| (n = 106) | (n = 110) | (n = 212) | (n = 193) | (n = 75) | (n = 88) | |
| FBG, mmol/L | ||||||
| 24 weeks | −1.30 (−1.65– −0.96) | −1.82 (−2.09– −1.54)* | −1.19 (−1.41– −0.96) | −1.80 (−2.03– −1.58)* | −1.55 (−1.84– −1.25) | −1.78 (−2.09– −1.46) |
| 48 weeks | −1.43 (−1.82– −1.06) | −1.85 (−2.22– −1.47) | −1.37 (−1.61– −1.12) | −1.73 (−1.99– −1.46)* | −1.33 (−1.71– −0.95) | −1.77 (−2.16– −1.37) |
| PBG, mmol/L | ||||||
| 24 weeks | −3.05 (−3.65– −2.45) | −2.79 (−3.49– −2.08) | −2.99 (−3.47– −2.51) | −2.48 (−2.95– −2.00) | −2.86 (−3.43– −2.29) | −2.59 (−3.18– −2.00) |
| 48 weeks | −2.93 (−3.58– −2.29) | −2.35 (−3.16– −1.54) | −3.34 (−3.83– −2.84) | −2.35 (−2.85– −1.85)** | −2.40 (−3.08– −1.71) | −2.47 (−3.11– −1.82) |
| FINS, uIU/mL | ||||||
| 24 weeks | −2.41 (−5.61– 0.79) | −3.67 (−5.25– −2.09) | −3.79 (−5.40– −2.18) | −4.63 (−6.00– −3.25) | −4.18 (−6.89– −1.47) | −2.57 (−5.20– 0.06) |
| 48 weeks | 0.94 (0.77– 1.46) | −4.30 (−6.08– −2.52) | −3.92 (−5.74– −2.10) | −3.43 (−5.86– −1.00) | −5.57 (−8.23– −2.90) | −3.58 (−6.29– −0.87) |
| HbA1C, % | ||||||
| 24 weeks | −1.15 (−1.44– −0.87) | −1.17 (−1.41– −0.93) | −1.09 (−1.26– −0.92) | −1.24 (−1.42– −1.06) | −1.18 (−1.44– −0.93) | −1.30 (−1.52– −1.07) |
| 48 weeks | −0.95 (−1.25– −0.65) | −1.10 (−1.38– −0.81) | −1.10 (−1.27– −0.93) | −1.21 (−1.42– −1.01) | −1.06 (−1.34– −0.78) | −1.21 (−1.46– −0.95) |
| HbA1C≤6.5%, % | ||||||
| 24 weeks | 67.0 | 64.6 | 65.1 | 64.4 | 80.6 | 75.3 |
| 48 weeks | 60.5 | 58.7 | 65.0 | 60.8 | 67.2 | 69.7 |
| HOMA-IR | ||||||
| 24 weeks | −1.56 (−2.61– −0.52) | −1.88 (−2.54– −1.23) | −1.80 (−2.31– −1.29) | −2.66 (−3.28– −2.04)* | −2.41 (−3.45– −1.38) | −1.92 (−2.80– −1.04) |
| 48 weeks | 0.94 (0.77– 1.46) | −2.21 (−2.88– −1.53) | −1.90 (−2.49– −1.31) | −2.08 (−3.08– −1.08) | −2.84 (−3.90– −1.79) | −2.03 (−3.07– −0.97) |
| HOMA-β | ||||||
| 24 weeks | 23.94 (−25.09– 72.97) | 2.93 (−4.93– 10.79) | 2.71 (−16.38– 21.79) | 11.29 (3.07– 19.50) | 16.52 (−2.14– 35.18) | 20.97 (4.49– 37.44) |
| 48 weeks | 41.26 (21.23– 61.95) | 4.74 (−5.32– 14.79) | 9.02 (−14.80– 32.84) | 7.72 (−10.32– 25.77) | 2.94 (−13.34– 19.21) | 12.44 (−1.09– 25.97) |
Data are shown as difference (95% CI) vs baseline. FBG: fasting blood glucose; PBG: 2 h post-challenge blood glucose; FINS: fasting insulin; HbA1C: hemoglobin A1c; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β cell function.
*significantly different at P <0.05 vs baseline;
**significantly different at P <0.01 vs baseline.